Sofinnova Investments’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Sofinnova Investments’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,002,348	Closed	-$23.2M	–	65
2023 Q1	$23.2M	Buy	1,002,348 +195,889	+24%	+$4.67M	1.48%	19
2022 Q4	$21.1M	Buy	806,459 +518,558	+180%	+$11.5M	1.25%	20
2022 Q3	$5.66M	Buy	287,901 +11,292	+4%	+$226K	0.33%	42
2022 Q2	$4.84M	Buy	+276,609	New	+$4.34M	0.4%	42
2018 Q4	–	Sell	-37,916	Closed	-$1.39M	–	71
2018 Q3	$1.39M	Sell	37,916 -10,348	-21%	-$332K	0.12%	56
2018 Q2	$1.69M	Buy	48,264 +44,925	+1,345%	+$1.72M	0.19%	51
2018 Q1	$155K	Buy	+3,339	New	+$122K	0.03%	51

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sofinnova Investments's KDNY Position: Q2 2023 in Review

Sofinnova Investments sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 1,002,348 shares — an estimated $23.2M sold.

Sofinnova Investments first reported a position in KDNY in Q1 2018 and held it in 7 quarters. The position peaked at $23.2M in Q1 2023. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Sofinnova Investments reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Sofinnova Investments sold 1,002,348 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $23.2M.
Sofinnova Investments first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2018 and held it in 7 quarters.
Sofinnova Investments's Chinook Therapeutics, Inc. Common Stock position peaked at $23.2M in Q1 2023.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Sofinnova Investments's 13F filing for Q2 2023, filed 14 Aug 2023.